MedElevator
Войти в исследования Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
Аннотация
In the Medical Research Council's IVth trial in Myelomatosis the possible benefit of adding vincristine to first line treatment with intermittent melphalan and prednisone has been assessed. This was analysed in 530 patients who were randomly allocated to receive vincristine or not. Survival was not improved by the addition of vincristine. A total of 268 patients reached plateau phase on first line therapy. Of these 226 patients were rerandomised either to continue receiving first line therapy for a further year or to cease therapy. At the present time there is a slight but not significant survival advantage in the group which received no further treatment on reaching plateau.
Перевод полного текста: Перевод в очереди
Полный текст источника
https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .
Alexanian R. Dreicer R. Chemotherapy for multiple myeloma. 53 3 1 2 1984 583 588 Cancer 6362819 10.1002/1097-0142(19840201)53:3<583::aid-cncr2820530336>3.0.co;2-1
Alexanian R. Gehan E. Haut A. Saiki J. Weick J. Unmaintained remissions in multiple myeloma. 51 6 6 1978 1005 1011 Blood 647110
Barlogie B. Smith L. Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. 310 21 24 5 1984 1353 1356 N Engl J Med 6546971 10.1056/NEJM198405243102104
Bonnet J. D. Alexanian R. Salmon S. E. Haut A. Dixon D. O. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. 68 3 3 1984 481 485 Cancer Treat Rep 6200220
Case D. C. Jr Lee D. J. 3rd Clarkson B. D. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. 63 6 12 1977 897 903 Am J Med 605911 10.1016/0002-9343(77)90543-5
Cooper E. H. Forbes M. A. Crockson R. A. MacLennan I. C. Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial. 37 8 8 1984 852 858 J Clin Pathol PMC498880 6206095 10.1136/jcp.37.8.852
Cornwell G. G. 3rd Pajak T. F. Kochwa S. McIntyre O. R. Glowienka L. P. Brunner K. Rafla S. Silver R. T. Cooper M. R. Henderson E. Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. 50 9 1 11 1982 1669 1675 Cancer 7116299 10.1002/1097-0142(19821101)50:9<1669::aid-cncr2820500902>3.0.co;2-n
Hokanson J. A. Brown B. W. Thompson J. R. Drewinko B. Alexanian R. Tumor growth patterns in multiple myeloma. 39 3 3 1977 1077 1084 Cancer 912647 10.1002/1097-0142(197703)39:3<1077::aid-cncr2820390311>3.0.co;2-s
Lee B. J. Sahakian G. Clarkson B. D. Krakoff I. H. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. 33 2 2 1974 533 538 Cancer 4812771 10.1002/1097-0142(197402)33:2<533::aid-cncr2820330231>3.0.co;2-z
Paccagnella A. Cartei G. Fosser V. Salvagno L. Bolzonella S. Chiarion Sileni V. Fiorentino M. V. Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. 19 10 10 1983 1345 1351 Eur J Cancer Clin Oncol 6688993 10.1016/0277-5379(93)90002-m
Salmon S. E. Expansion of the growth fraction in multiple myeloma with alkylating agents. 45 1 1 1975 119 129 Blood 803104
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.